TOP

LOGIN
Press/Media

Gen Re Announces 2023 U.S. Group Medical Evidence of Insurability Underwriting Survey Results

Issue: June 2023 | Life/Health North America

Top challenges found to be managing volume, inefficient underwriting systems, and technology deficiencies.

Portland, Maine, June 26, 2023 – Gen Re has released results of the 2023 U.S. Group Medical Evidence of Insurability Underwriting Survey. The survey focuses on what staff companies provide to process Evidence of Insurability (EOI) applications as well as the methods used to process them, providing companies with an opportunity to benchmark their results against those of the industry. Twenty-three companies participated in this year’s survey.

Key results from this year’s survey include:

  • Participants reported receiving a total of over 2.6 million EOI applications in 2022.
  • The average processing time for an EOI application is 15 business days (excluding automated or straight-through processing).
  • Many companies report having an automated or straight-through processing EOI system. However, a significant number of applications are still being reviewed by a medical underwriter.
  • The top challenges facing group medical underwriting departments are managing volume during peak times, inefficient underwriting systems, and technology deficiencies.

The comprehensive report is available only to participating companies. A summary report is available here.

Gen Re, a Berkshire Hathaway Company, is one of the leading Life & Health and Property & Casualty reinsurers in the world. Our North American Life & Health reinsurance company, General Re Life Corporation, has superior financial strength ratings among Life and Health reinsurers. Gen Re delivers customized reinsurance programs and risk management solutions for the Life, Medicare Supplement, Critical Illness and Individual Disability Income markets. Through our research, we also offer valuable information and insights.

Contact